STOCK TITAN

Guardant Health (NASDAQ: GH) director sells 1,700 shares after option exercise

(Moderate)
(Negative)
Form Type
4

Rhea-AI Filing Summary

Guardant Health director Manuel Hidalgo Medina exercised stock options for 950 shares on August 5, 2026 at an exercise price of $32.5500 per share, receiving 950 common shares. He then sold 1,700 common shares in two trades at $163.9450 and $164.6051 per share. After the exercise, he continued to hold stock options covering 12,079 shares that were granted on July 17, 2024 and vest 25% on July 17, 2025, with the remaining 75% vesting monthly over the following three years.

Positive

  • None.

Negative

  • None.
Insider Hidalgo Medina Manuel
Role Director
Sold 1,700 shs ($279K)
Approx. gross sale proceeds $279K
Approx. exercise cost $31K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F1 950 $0.00 $0.00
Exercise Common Stock 950 $32.55 $31K
Sale Common Stock 950 $163.945 $156K
Sale Common Stock 750 $164.6051 $123K
Holdings After Transaction: Stock Option (Right to Buy) — 12,079 shares (Direct); Common Stock — 4,556 shares (Direct)
Footnotes (1)
  1. F1. The stock option granted on July 17, 2024 vests over a four-year period. 25% of the shares subject to such award vested on July 17, 2025 and the remaining 75% vests monthly for the three-year period thereafter.
Shares sold at $163.9450 950 shares Common Stock sale on 2026-08-05 at $163.9450 per share
Shares sold at $164.6051 750 shares Common Stock sale on 2026-08-05 at $164.6051 per share
Total shares sold 1,700 shares Aggregate Common Stock sales on 2026-08-05
Shares acquired via option exercise 950 shares Stock Option (Right to Buy) exercised at $32.5500 on 2026-08-05
Option exercise price $32.5500 per share Conversion or exercise price of Stock Option (Right to Buy)
Options held after exercise 12079 shares Total shares underlying Stock Option (Right to Buy) following exercise
Option expiration date 2034-07-17 Expiration date of the Stock Option (Right to Buy) grant
Stock Option (Right to Buy) financial
"Security title reported as Stock Option (Right to Buy)"
derivative security financial
"Transaction code M described as Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vests over a four-year period financial
"The stock option granted on July 17, 2024 vests over a four-year period"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transactions did GH director Manuel Hidalgo Medina report on August 5, 2026?

Manuel Hidalgo Medina reported exercising options for 950 Guardant Health (GH) shares at $32.5500 and then selling 1,700 common shares in two trades at $163.9450 and $164.6051 per share, all dated August 5, 2026.

How many Guardant Health (GH) shares did the director sell, and at what prices?

He sold a total of 1,700 GH common shares: 950 shares at $163.9450 per share and 750 shares at $164.6051 per share. These sales followed the same-day exercise of stock options for 950 shares.

What stock options did the GH director exercise in this Form 4 filing?

He exercised a Stock Option (Right to Buy) for 950 shares of Guardant Health common stock at an exercise price of $32.5500 per share. The option expires on July 17, 2034 and was part of a 2024 grant with multi-year vesting.

How many Guardant Health (GH) stock options does the director hold after these transactions?

Following the reported option exercise, he continued to hold stock options for 12,079 shares of Guardant Health common stock. These options relate to a grant dated July 17, 2024, which vests over a four-year period through monthly installments.

What is the vesting schedule of the Guardant Health (GH) stock option mentioned in the Form 4?

The stock option granted on July 17, 2024 vests over four years: 25% of the shares vested on July 17, 2025, and the remaining 75% vests in equal monthly installments over the following three years, subject to continued service.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hidalgo Medina Manuel

(Last)(First)(Middle)
3100 HANOVER STREET

(Street)
PALO ALTO CALIFORNIA 94304

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/05/2026M950A$32.556,256D
Common Stock08/05/2026S950D$163.9455,306D
Common Stock08/05/2026S750D$164.60514,556D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$32.5508/05/2026M950 (1)07/17/2034Common Stock950$012,079D
Explanation of Responses:
1. The stock option granted on July 17, 2024 vests over a four-year period. 25% of the shares subject to such award vested on July 17, 2025 and the remaining 75% vests monthly for the three-year period thereafter.
Remarks:
/s/ John G. Saia, as attorney-in-fact for Manuel Hidalgo Medina08/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)